Everlywell HPV Test services are expanding through a new partnership with Waters Corporation. Everlywell, a leader in digital health, announced the collaboration to improve access to cervical cancer screening. The partnership will provide patients access to the Onclarity™ HPV Self-Collection Kit. The kit uses the BD Onclarity™ HPV Assay for testing. The companies describe the solution as the most comprehensive FDA-cleared at-home HPV cervical cancer screening tool available in the United States today.¹
The new diagnostic-led solution will support health plans as they expand preventive care access. It will also help eligible members complete recommended cervical cancer screening. Furthermore, the partnership connects screening with follow-up care and clinical guidance. Members can collect their samples at home and send them to a CLIA-certified laboratory. The laboratory will process the samples and provide testing results.
Patients will receive their results digitally through the Everlywell platform. Eligible members can also access clinical follow-up through telehealth consultations. When results require additional evaluation, the care pathway includes in-person referrals. This approach aims to make cervical cancer screening more convenient for eligible members. It also helps health plans connect screening services with appropriate medical support.
“Every woman deserves a clear and accessible path to understand her health and take the next right step. The new partnership expands access to screening, and connects women to appropriate follow-up care,” said Julia Cheek, Founder and CEO of Everlywell. “By bringing together outreach, convenient screening access, clinician-guided results, and connected care systems, we can help plans close care-gaps while preparing for the next generation of women’s preventive care.”
Everlywell HPV Test Addresses Cervical Cancer Screening Gaps
Cervical cancer screening remains an important part of preventive women’s healthcare. However, many women still face challenges when accessing recommended testing. The American Cancer Society estimates that more than 13,000 invasive cervical cancer cases will occur in the United States this year.² Screening and HPV vaccination have improved cervical cancer prevention and detection. Nevertheless, significant gaps in screening access continue.
Approximately one in four women is not up to date with cervical cancer testing. In addition, around half of women diagnosed with cervical cancer have never received screening. Others are overdue for recommended testing. Cervical cancer rarely develops in women who receive regular screening before age 65.² Therefore, improving access to preventive testing remains an important healthcare priority.
Traditional cervical cancer screening often requires an in-person appointment. This requirement can create challenges for women with limited access to healthcare services. It can also affect members who face scheduling difficulties or hesitate to visit a clinic. The Everlywell HPV Test offers an at-home sample collection option. Members can complete the collection process from their homes. They can then send their samples to a CLIA-certified laboratory for testing.
The Everlywell platform delivers results digitally. Additionally, the service provides access to telehealth consultations for clinical follow-up. Members with abnormal results can receive in-person referrals for further evaluation. This connected approach supports a more accessible screening experience. It also helps health plans link preventive testing with appropriate care pathways.
FDA-Cleared HPV Testing Supports Health Plan Initiatives
Everlywell is among the first companies to bring an FDA-cleared at-home HPV testing solution to market. The company introduced the solution in response to the NCQA MY2026 update. The Cervical Cancer Screening–Electronic Clinical Data Systems measure, known as CCS-E, remains challenging for many health plans. Traditional screening requirements can make it difficult to reach members who need testing.
The Everlywell HPV Test provides another option for eligible members. It supports people who are overdue for screening or difficult to reach. It may also help members who prefer at-home testing over traditional office visits. By connecting screening activities with care pathways, the solution supports health plans’ preventive care efforts. It is designed to help plans address CCS-E care gaps.
The solution also supports preparation for updated federal preventive-services guidance. The guidance is scheduled to take effect in 2027. Health plans continue to seek new ways to improve preventive care engagement. At-home diagnostics can support these efforts by reducing certain access barriers. Moreover, digital result delivery can help connect members with follow-up services.
Everlywell and Waters Corporation are combining diagnostic testing with digital healthcare services. Their partnership focuses on improving access to cervical cancer screening. It also supports health plans as they develop more connected care experiences.
Onclarity HPV Self-Collection Kit Provides Comprehensive Testing
The Onclarity™ HPV Self-Collection Kit uses the BD Onclarity™ HPV Assay. The assay detects 14 high-risk HPV genotypes associated with oncogenic risk.¹ According to the companies, the assay offers detailed genotype identification. It identifies six individual HPV genotypes and three groups of pooled results. The companies describe it as the most comprehensive HPV screening tool available in the United States today.¹ The testing approach provides information that can support cervical cancer screening. It also helps clinicians assess results and determine appropriate follow-up.
The partnership brings this testing capability into an at-home screening pathway. Members can collect samples without visiting a healthcare facility for sample collection. They can then send samples to a CLIA-certified laboratory. The Everlywell platform delivers results digitally after laboratory testing. Members can also access clinical support through telehealth consultations. When necessary, healthcare professionals can direct members toward in-person evaluation.
This process supports the connection between diagnostic testing and ongoing care. It also gives health plans another option for engaging eligible members. At-home HPV screening can help address practical barriers to preventive testing. However, members should follow clinical guidance after receiving their results. Abnormal results may require additional evaluation through an in-person healthcare provider.
Everlywell Expands Digital Health and Preventive Care Services
The Everlywell HPV Test forms part of the company’s wider preventive healthcare strategy. Everlywell continues to expand access to cancer screening and women’s health services. The company’s consumer and enterprise offerings cover several healthcare testing categories. These include cancer screenings and cardiometabolic screenings. They also include fertility-related testing and hormone and thyroid biomarkers.
Everlywell provides sexual-health testing services as well. Its platform delivers health information through digital channels. The company designs its services to help eligible individuals understand their results. The platform also supports informed decisions about medical follow-up. When necessary, individuals can pursue appropriate care with healthcare professionals.
For health plans, these services can support member engagement. They can also help organizations connect members with preventive healthcare resources. The partnership with Waters Corporation strengthens Everlywell’s focus on women’s health. It also expands the company’s role in digital diagnostic services. The companies aim to make cervical cancer screening more accessible. They also seek to support health plans with connected screening and care pathways.
Everlywell has spent more than a decade developing consumer and health plan healthcare solutions. The company combines digital technology with human insight and advanced diagnostics. Its services also include virtual care and patient engagement capabilities. These tools help individuals understand their health information. They also support informed and actionable next steps.
Through the partnership, Everlywell and Waters Corporation are addressing important screening access challenges. The collaboration connects at-home testing with digital results and clinical follow-up. As a result, the Everlywell HPV Test supports a broader approach to preventive women’s healthcare. The solution also reflects the growing role of digital health in diagnostic access.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
